AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering

$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering.

Laidlaw & Company (UK) Ltd. is acting as lead manager for the offering.

View Press Release Here